[1] Matsuoka K, Nishiumi S, Yoshida M, et al. Effects of helicobacter pylori on the glutathione-related pathway in gastric epithelial cells[J]. Biochem Res Commun, 2020, 526(4):1118-1124.
[2] Kavitt R T, Lipowska A M, Anyane Y A, et al. Diagnosis and treatment of peptic ulcer disease[J]. Am J Med, 2019, 132(4):447-456.
[3] Safavi M, Sabourian R, Foroumadi A. Treatment of helicobacter pylori infection: current and future insights[J]. World J Clin Cases, 2016, 4(1):5-19.
[4] Santos M L, de Brito B B, da Silva F A, et al. Helicobacter pylori infection: Beyond gastric manifestations[J]. World J Gastroenterol, 2020, 26(28):4076-4093.
[5] Brennan D E, Dowd C, O’Morain C, et al. Can bacterial virulence factors predict antibiotic resistant Helicobacter pylori infection? [J]. World J Gastroenterol, 2018, 24(9):971-981.
[6] Muzaheed.Helicobacter pylori oncogenicity: mechanism, prevention, and risk factors[J]. Sci World J, 2020:3018326.
[7] Karabiber H, Selimoglu M A, Otlu B, et al. Virulence factors and antibiotic resistance in children with Helicobacter pylori gastritis[J]. J Pediatr Gastroenterol Nutr, 2014, 58(5):608-612.
[8] Haddadi M H, Negahdari B, Asadolahi R, et al. Helicobacter pylori antibiotic resistance and correlation with caga motifs and homb gene[J]. Postgrad Med, 2020, 132(6):512-520.
[9] Oktem O S, Cekic K Z, Kilic E, et al. Analysis of correlation between the seven important helicobacter pylori (h. pylori) virulence factors and drug resistance in patients with gastritis[J]. Gastroenterol Res Pract, 2020, 2020:3956838.
[10] Khademi F, Sahebkar A. An updated systematic review and meta-analysis on the helicobacter pylori antibiotic resistance in iran (2010-2020)[J]. Microb Drug Resist, 2020, 26(10):1186-1194.
[11] 齐 乐,唐 敏,汪文生,等.慢性萎缩性胃炎患者幽门螺杆菌感染情况调查及其耐药性分析[J].中国病原生物学杂志,2021,16(10):1216-1219.
[12] Ji J, Yang H. In Vitro effects of lactobacillus plantarum ln66 and antibiotics used alone or in combination on helicobacter pylori mature biofilm[J]. Microorganisms, 2021, 9(2):424.
[13] Yan J, Bassler B L. Surviving as a community: antibiotic tolerance and persistence in bacterial biofilms[J]. Cell Host Microbe, 2019, 26(1):15-21.
[14] Hathroubi S, Servetas S L, Windham I, et al. Helicobacter pylori biofilm formation and its potential role in pathogenesis[J]. Microbiol Mol Biol Rev, 2018, 82(2):e1-18.
[15] Servetas S L, Doster R S, Kim A, et al. ArsRS-dependent regulation of homb contributes to helicobacter pylori biofilm formation[J]. Front Microbiol, 2018, 9:1497.
[16] Tamrakar A, Singh R, Kumar A, et al. Biophysical characterization of the homodimers of homa and homb, outer membrane proteins of helicobacter pylori[J]. Sci Rep, 2021, 11(1):24471.
[17] Anderson J K, Huang J Y, Wreden C, et al. Chemorepulsion from the quorum signal autoinducer-2 promotes helicobacter pylori biofilm dispersal[J]. mBio, 2015, 6(4):e00379.
[18] Wong E H, Ng C G, Goh K L, et al. Metabolomic analysis of low and high biofilm-forming Helicobacter pylori strains[J]. Sci Rep, 2018, 8(1):1409.
[19] 阿里健康上线国内首个幽门螺杆菌自测产品“幽幽管”,10 min出结果[EB/OL].(2021-12-10)[2021-12-10]. https://baijiahao.baidu.com/s?id=1722172006274063623&wfr=spider&for=pc 2022-01-17
[20] Li Y, Lv T, He C, et al. Evaluation of multiplex ARMS-PCR for detection of helicobacter pylori mutations conferring resistance to clarithromycin and levofloxacin[J]. Gut Pathog, 2020, 12:35.
[21] Yang H, Hu B. Diagnosis of Helicobacter pylori Infection and recent advances[J]. Diagnostics (Basel), 2021, 11(8):1305.
[22] Yin G, Bie S, Gu H, et al. Application of gene chip technology in the diagnostic and drug resistance detection of helicobacter pylori in children[J]. J Gastroenterol Hepatol, 2020, 35(8):1331-1339.
[23] Suez J, Zmora N, Segal E, et al. The pros, cons, and many unknowns of probiotics[J]. Nat Med, 2019,25(5):716-729.
[24] Dargenio C, Dargenio V N, Bizzoco F, et al. Limosilactobacillus reuteri strains as adjuvants in the management of helicobacter pylori infection[J]. Medicina (Kaunas), 2021, 57(7):733.
[25] McFarland L V, Evans C T, Goldstein E J. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis[J]. Front Med (Lausanne), 2018, 5:124.
[26] Shi X, Zhang J, Mo L, et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis[J]. Medicine (Baltimore), 2019, 98(15):e15180.
[27] Ortigão R, Pimentel N P, Dinis R M, et al. Gastrointestinal microbiome-what we need to know in clinical practice[J]. GE Port J Gastroenterol, 2020, 27(5):336-351.
[28] Song H, Zhang J, Qu J, et al. Lactobacillus rhamnosus GG microcapsules inhibit Escherichia coli biofilm formation in coculture[J]. Biotechnol Lett, 2019, 41(8-9):1007-1014.
[29] Jung S, Park O J, Kim A R, et al. Lipoteichoic acids of lactobacilli inhibit enterococcus faecalis biofilm formation and disrupt the preformed biofilm[J]. J Microbiol, 2019, 57(4):310-315.
[30] Zagari R M, Romiti A, Ierardi E, et al. The “three-in-one” formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice[J]. Helicobacter, 2018, 23(4):e12502.
[31] Malfertheiner P, Selgrad M, Wex T, et al. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study[J]. Lancet Gas Hepatol, 2018, 3(10):698-707.
[32] Iankov I D, Kurokawa C, Viker K, et al. Live Attenuated measles virus vaccine expressing helicobacter pylori heat shock protein A[J]. Mol Ther Oncolytics, 2020, 19:136-148.
[33] Safavi M, Sabourian R, Foroumadi A. Treatment of helicobacter pylori infection: current and future insights[J]. World J Clin Cases, 2016, 4(1):5-19.
[34] Zeng M, Mao X H, Li J X, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet,2015,386(10002):1457-1464.
[35] Khan M, Khan S, Ali A, et al. Immunoinformatics approaches to explore helicobacter pylori proteome (virulence factors) to design b and t cell multi-epitope subunit vaccine[J]. Sci Rep, 2019, 9(1):13321.
[36] Ghosh P, Bhakta S, Bhattacharya M, et al. A Novel multi-epitopic peptide vaccine candidate against helicobacter pylori: in-silico identification, design, cloning and validation through molecular dynamics[J]. Int J Pept Res Ther, 2021, 27(2):1149-1166.
[37] Nikolich M P, Filippov A A. Bacteriophage therapy: developments and directions[J]. Antibiotics (Basel), 2020, 9(3):135.
[38] Lin D M, Koskella B, Lin H C. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance[J]. World J Gastrointest Pharmacol Ther, 2017, 8(3):162-173.
[39] Takeuchi H, Kira M, Konishi S, et al. Polymorphisms in the Helicobacter pylori NY43 strain and its prophage-cured derivatives[J]. Microbiology (Reading), 2018,164(6):877-882.
[40] You Y, He L, Zhang M, Zhang J. Comparative genomics of a Helicobacter pylori isolate from a Chinese yunnan naxi ethnic aborigine suggests high genetic divergence and phage insertion[J]. PLoS One, 2015, 10(3):e0120659.
[41] Solovieva E V, Myakinina V P, Kislichkina A A, et al. Comparative genome analysis of novel podoviruses lytic for hypermucoviscous klebsiella pneumoniae of K1, K2, and K57 capsular types[J]. Virus Res, 2018, 243:10-18.